Actavis Plc (AGN) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2013

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Allergan Plc
Ticker: AGN CIK: 1578845

Exhibit 99.1

LOGO

NEWS RELEASE

CONTACTS:

Investors:

Lisa DeFrancesco

(862) 261-7152

Media:

Charlie Mayr

(862) 261-8030

David Belian

(862) 261-8141

Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013;

Non-GAAP EPS Increases 99% to $3.17

- Fourth Quarter 2013 GAAP Loss Per Share of $0.86 -

- 108% Increase in Fourth Quarter 2013 Adjusted EBITDA to $817 million -

- Company affirms 2014 forecast -

DUBLIN – February 20, 2014 –

Actavis plc (NYSE: ACT) today reported net revenue increased 59 percent to $2.779 billion for the fourth quarter ended December 31, 2013, compared to $1.75 billion in the fourth quarter 2012. On a non-GAAP basis, diluted earnings per share for the fourth quarter 2013 increased to $3.17, compared to $1.59 per diluted share in the fourth quarter 2012. GAAP loss per share for the fourth quarter 2013 was $0.86, compared to GAAP earnings per diluted share of $0.21 in the prior year period.

For the fourth quarter 2013, adjusted EBITDA increased 108 percent to $817.1 million, compared to $393.0 million for the fourth quarter 2012. Cash flow from operations for the fourth quarter of 2013 was $651.7 million and cash and marketable securities were $331.5 million as of December 31, 2013.

For the full year 2013, net revenue increased 47 percent to $8.7 billion, compared to net revenue of $5.9 billion for full year 2012. On a non-GAAP basis, 2013 earnings per diluted share increased 58 percent to $9.50 per diluted share compared $6.00 per diluted share in 2012. Full-year 2013 GAAP loss per share

The following information was filed by Allergan Plc (AGN) on Thursday, February 20, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Allergan Plc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Allergan Plc.

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1578845/000119312514066242/d648811d10k.htm